Patrick M Sweeney & Associates Inc. Has $654,000 Stock Holdings in Novo Nordisk A/S $NVO

Patrick M Sweeney & Associates Inc. reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 15.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,455 shares of the company’s stock after selling 1,700 shares during the period. Patrick M Sweeney & Associates Inc.’s holdings in Novo Nordisk A/S were worth $654,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. Stone House Investment Management LLC acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $30,000. NewSquare Capital LLC boosted its holdings in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares in the last quarter. Disciplina Capital Management LLC grew its position in Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 297 shares during the last quarter. Dagco Inc. bought a new stake in Novo Nordisk A/S during the 1st quarter worth $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S in the 2nd quarter worth about $37,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. HSBC cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target on the stock in a report on Wednesday, August 13th. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Finally, BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $57.40.

Novo Nordisk A/S Stock Up 3.6%

Shares of Novo Nordisk A/S stock opened at $48.75 on Friday. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $112.52. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The stock’s 50-day moving average is $53.05 and its 200 day moving average is $59.86. The firm has a market cap of $217.67 billion, a price-to-earnings ratio of 13.39, a PEG ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.